Profile data is unavailable for this security.
About the company
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
- Revenue in USD (TTM)18.22m
- Net income in USD-71.18m
- Incorporated2003
- Employees133.00
- LocationAC Immune SAEPFL Innovation Park, Building BLAUSANNE 1015SwitzerlandCHE
- Phone+41 213459121
- Fax+41 213459120
- Websitehttps://www.acimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 0.00 | -92.22m | 337.83m | 92.00 | -- | 1.70 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Voyager Therapeutics Inc | 143.77m | 9.02m | 340.83m | 162.00 | 40.74 | 1.02 | 24.54 | 2.37 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Cartesian Therapeutics Inc | 54.10m | -229.65m | 342.76m | 38.00 | -- | -- | -- | 6.34 | -38.41 | -38.41 | 5.07 | -5.69 | 0.2221 | -- | 2.89 | 1,423,737.00 | -94.26 | -43.66 | -106.38 | -66.84 | -- | -- | -424.47 | -136.35 | -- | -0.3153 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.87m | 349.99m | 10.00 | -- | 3.56 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 356.40m | 58.00 | -- | 2.16 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -88.56m | 359.47m | 59.00 | -- | 3.77 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Jasper Therapeutics Inc | 0.00 | -62.44m | 360.71m | 45.00 | -- | 3.60 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| AC Immune SA | 18.22m | -71.18m | 365.09m | 133.00 | -- | 2.52 | -- | 20.04 | -0.755 | -0.755 | 0.1968 | 1.46 | 0.0787 | -- | 28.76 | 136,985.20 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Nkarta Inc | 0.00 | -107.91m | 367.61m | 150.00 | -- | 0.8112 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Alto Neuroscience Inc | -100.00bn | -100.00bn | 369.07m | 78.00 | -- | 2.05 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 369.68m | 28.00 | -- | 7.22 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Organogenesis Holdings Inc | 448.39m | -16.54m | 375.19m | 862.00 | -- | 1.42 | -- | 0.8367 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 383.97m | 49.00 | -- | 1.93 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -69.64m | 386.27m | 164.00 | -- | 1.64 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Lyell Immunopharma Inc | 54.00k | -210.26m | 386.56m | 224.00 | -- | 0.6822 | -- | 7,158.61 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to AC Immune SA's reporting currency: US Dollar USD
27.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 18.83m | 18.90% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 1.91m | 1.92% |
| Redmile Group LLCas of 30 Jun 2024 | 1.81m | 1.81% |
| Wells Fargo Clearing Services LLCas of 30 Jun 2024 | 1.12m | 1.13% |
| Platinum Investment Management Ltd.as of 30 Jun 2024 | 952.07k | 0.96% |
| Avidity Partners Management LPas of 30 Jun 2024 | 825.00k | 0.83% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 652.08k | 0.65% |
| Assenagon Asset Management SA (Germany)as of 30 Jun 2024 | 439.73k | 0.44% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 420.37k | 0.42% |
| DWS Investment GmbHas of 30 Jun 2024 | 253.38k | 0.25% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
